Daily Respiratory Research Analysis
A network meta-analysis of randomized trials in pediatric critical asthma identifies intravenous magnesium sulfate as the leading adjunctive therapy, reducing hospital and PICU utilization. A multicenter prospective cohort shows that survivors of COVID-19 ARDS have persistent symptoms and high rates of post-exertional malaise at 3 years. A multicenter randomized, double-blind trial found simvastatin did not reduce postoperative cardiopulmonary complications in one-lung ventilation surgeries.
Summary
A network meta-analysis of randomized trials in pediatric critical asthma identifies intravenous magnesium sulfate as the leading adjunctive therapy, reducing hospital and PICU utilization. A multicenter prospective cohort shows that survivors of COVID-19 ARDS have persistent symptoms and high rates of post-exertional malaise at 3 years. A multicenter randomized, double-blind trial found simvastatin did not reduce postoperative cardiopulmonary complications in one-lung ventilation surgeries.
Research Themes
- Pediatric critical asthma adjunctive therapies
- Long-term outcomes and PEM in post-COVID-19 ARDS
- Perioperative lung protection strategies in one-lung ventilation
Selected Articles
1. Intravenous Bronchodilators in Pediatric Critical Asthma: A Systematic Review and Network Meta-Analysis.
This network meta-analysis of 12 RCTs (n=852) compared IV adjunct bronchodilators in pediatric critical asthma and found that IV magnesium sulfate achieved the largest reductions in hospital length of stay, PICU admission, and PICU length of stay. The results provide a ranking framework to guide first- and second-line IV adjunct choices when inhaled SABA and systemic steroids are insufficient.
Impact: Synthesizing randomized evidence, this study offers comparative effectiveness and a practical ranking for IV adjuncts in pediatric critical asthma, potentially harmonizing protocols and improving outcomes.
Clinical Implications: Consider IV magnesium sulfate as the preferred first-line IV adjunct when escalating care in pediatric critical asthma after inhaled SABA and systemic steroids. Protocols should incorporate MgSO4 dosing and monitoring, reserving alternative IV agents as second-line based on patient response and contraindications.
Key Findings
- Across 12 RCTs (n=852), IV magnesium sulfate was associated with the largest reductions in hospital length of stay, PICU admission, and PICU length of stay compared with other IV adjuncts.
- The analysis provides a ranked hierarchy of IV bronchodilators for pediatric critical asthma, supporting first- and second-line selection.
- The study addresses a gap in guideline recommendations by offering comparative evidence beyond placebo-controlled data.
Methodological Strengths
- Network meta-analysis integrating randomized controlled trials to enable indirect and direct comparisons
- Systematic, multi-database search with predefined outcomes relevant to patient care (LOS, PICU utilization)
Limitations
- Heterogeneity in trial protocols, dosing, and co-interventions may influence pooled estimates
- Limited head-to-head comparisons and small sample sizes in some trials reduce precision
Future Directions: Prospective, adequately powered head-to-head RCTs comparing IV magnesium sulfate with other IV adjuncts (e.g., aminophylline, terbutaline) using standardized dosing, safety endpoints, and patient-centered outcomes.
INTRODUCTION: Pediatric critical asthma is one of the most common pediatric illnesses in children admitted to the pediatric ward and pediatric intensive care unit (PICU). Adjunct intravenous (IV) bronchodilators are often used when initial management with systemic corticosteroids and inhaled short-acting beta agonists (SABA) fail to provide improvement in a patient's clinical condition. While the recent guidelines gave recommendations for the use of different IV bronchodilators compared to placebo, it did not include ranking on which one should be used as first-line or second-line agent. The aim of this network meta-analysis is to determine the effect of IV bronchodilators on patient-centered outcomes and rank medications based on their effectiveness in these outcomes. METHODS: A systematic review was conducted using three databases MEDLINE, Embase, and CINAHL to identify randomized control trials examining the use of IV magnesium sulfate (MgSO RESULTS: Twelve trials (n = 852) were included in the network meta-analysis. Largest reduction in hospital length of stay (LOS), PICU admission, and PICU LOS were noted with IV MgSO CONCLUSIONS: In this network meta-analysis comparing different IV adjunct bronchodilators, IV MgSO
2. Health outcomes up to 3 years and post-exertional malaise in patients after hospitalization for COVID-19: a multicentre prospective cohort study (CO-FLOW).
In 299 hospitalized COVID-19 survivors followed for 3 years, complete recovery rose from 12% at 3 months to 24% at 3 years, yet fatigue, impaired fitness, and cognitive problems remained common. Post-exertional malaise affected 36% at 3 years and was associated with female sex, pre-existing pulmonary disease, pre-COVID inactivity, and ICU treatment; fatigue and mental HRQoL worsened between years 2 and 3 in those with PEM.
Impact: This is among the longest multicenter prospective cohorts detailing trajectories and PEM in post-COVID-19 ARDS survivors, quantifying persistent symptom burden and identifying modifiable risk factors.
Clinical Implications: Implement long-term follow-up of COVID-19 ARDS survivors with routine screening for PEM, fatigue, sleep quality, and cognitive impairment. Rehabilitation plans should be individualized, with pacing for PEM and targeted interventions for those with identified risk factors (e.g., pre-existing pulmonary disease).
Key Findings
- At 3 years, only 24% reported complete recovery; 66% had fatigue, 63% impaired fitness, 59% memory problems, and 53% concentration problems.
- PEM prevalence was 36% at 3 years; independent risk factors included female sex (OR 3.4), pre-existing pulmonary disease (OR 3.0), pre-COVID inactivity (OR 2.3), and ICU treatment (OR 1.8).
- Between 2 and 3 years, memory problems (OR 1.4), fatigue score (+1.0), cognitive failures (+2.2), and SF-36 MCS (−2.2) significantly worsened.
Methodological Strengths
- Multicenter prospective cohort with repeated measures up to 36 months
- Use of generalized estimating equations and multivariable modeling to assess trajectories and risk factors
Limitations
- Reliance on patient-reported outcomes without systematic objective cognitive testing
- Potential selection and attrition biases; lack of non-hospitalized control group
Future Directions: Trials testing PEM-informed rehabilitation (pacing), cognitive-behavioral, and pharmacologic interventions; biomarker and mechanistic studies to clarify pathophysiology underpinning long COVID and PEM.
BACKGROUND: Many patients experience long-lasting health problems after COVID-19. The study aimed to assess 3-year trajectories of a comprehensive set of patient-reported outcome measures (PROMs) in patients hospitalized for COVID-19, particularly focusing on the 2- to 3-year trajectory. Additionally, we evaluated prevalence of post-exertional malaise (PEM) at 3 years, its risk factors, co-occurring health problems, and the 3-year trajectories of patients with and without PEM. METHODS: The CO-FLOW multicentre prospective cohort study followed up adults hospitalized for COVID-19 in 7 hospitals, located in the Netherlands. Study assessments were performed at 3, 6, 12, 24, and 36 months post-discharge, conducted between July 1, 2020, and May 22, 2024. PROMs on recovery, symptoms, fatigue, mental health, cognition, participation, sleep quality, work status, health-related quality of life (HRQoL), and PEM were collected. Generalized estimating equations were used to assess health trajectories and multivariable logistic regression to identify risk factors for PEM. FINDINGS: In total, 299/344 (87%) patients completed the 3-year follow-up and were included in the analysis. Complete recovery rates increased (p < 0.001), from 12% at 3 months to 24% at 3 years. Symptoms of impaired fitness, fatigue, and muscle weakness (all p < 0.0019) and PROMs for fatigue score, participation, return to work, and HRQoL (all p < 0.005) improved significantly over time, while PROMs for cognitive failures worsened (p < 0.001). Between the 2- and 3-year visits, memory problems (OR 1.4 [1.1-1.7], p < 0.001), and scores of fatigue (MD +1.0 [0.4-1.6], p = 0.002), cognitive failures (MD +2.2 [0.9-3.4], p < 0.001), and SF-36 mental component summary (-2.2 [-3.1 to -1.3], p < 0.001) significantly worsened. At 3 years, 66% of patients experienced fatigue, 63% impaired fitness, 59% memory problems, and 53% concentration problems. PROMs showed that 62% reported poor sleep quality, 55% fatigue, and 28% cognitive failures. PEM was reported by 105/292 (36%) patients at 3 years; risk factors were female sex (OR 3.4 [95% CI 1.9-6.0], p < 0.001), pre-existing pulmonary disease (3.0 [1.7-5.6], p < 0.001), physical inactivity pre-COVID-19 (2.3 [1.2-4.1], p = 0.008), and ICU treatment for COVID-19 (1.8 [1.02-3.0], p = 0.04). Concurrent fatigue, cognitive failures, and dyspnea were more common in patients with (42%) than without (6%) PEM. Patients with PEM showed poor health outcomes throughout the entire follow-up period, including worsening fatigue and HRQoL during the third year. INTERPRETATION: Many health problems persisted up to 3 years post-discharge, with self-reported fatigue and cognitive problems worsening in the third year. PEM was common, and linked to a more severe phenotype of long COVID. These findings highlight the urgent need to optimize treatment options and investigate underlying pathological mechanisms of COVID-19. FUNDING: The Netherlands Organisation for Health Research and Development (ZonMw); Rijndam Rehabilitation; Laurens.
3. Effect of simvastatin on postoperative complications in patients undergoing one-lung ventilation during surgery: the Prevention HARP-2 randomised controlled trial.
In this multicenter randomized, double-blind trial in surgeries requiring one-lung ventilation, perioperative simvastatin (80 mg) did not reduce a composite endpoint of ARDS, postoperative pulmonary complications, or myocardial infarction/ischemia within 7 days compared with placebo. The study was stopped early for futility, and safety outcomes were similar.
Impact: Provides high-quality negative evidence against routine perioperative simvastatin for preventing cardiopulmonary complications in one-lung ventilation surgeries, guiding resource allocation and protocol design.
Clinical Implications: Do not add simvastatin solely for prophylaxis of postoperative cardiopulmonary complications in one-lung ventilation procedures. Focus on evidence-based lung-protective ventilation, fluid strategies, and enhanced recovery pathways.
Key Findings
- Modified intention-to-treat analysis (n=208): composite cardiopulmonary endpoint occurred in 42.5% with simvastatin versus 38.2% with placebo (OR 1.19; p=0.54).
- Trial halted early for futility; no differences in secondary or safety outcomes.
- Dosing: simvastatin 80 mg from 4 days pre-op to up to 7 days post-op; surgeries included oesophagectomy, lobectomy, pneumonectomy.
Methodological Strengths
- Randomized, double-blind, multicenter design with prespecified composite clinical endpoint
- Modified intention-to-treat analysis reflecting real-world operative deviations
Limitations
- Early termination reduced statistical power to detect modest effects
- Composite endpoint may mask differential effects on individual components
Future Directions: Focus on alternative perioperative lung-protective strategies and targeted anti-inflammatory approaches with mechanistic endpoints; consider biomarker-enriched or high-risk subgroups for future trials.
RATIONALE: Surgeries that require one-lung ventilation have high rates of postoperative cardiopulmonary complications with associated morbidity and mortality. Statins may limit inflammation involved in the development of these complications. OBJECTIVES: We tested the hypothesis that perioperative simvastatin use reduces postoperative cardiopulmonary complications, compared with placebo, in surgery requiring one-lung ventilation. METHODS: Randomised, double-blind, multicentre trial of simvastatin versus placebo in patients undergoing elective oesophagectomy, lobectomy or pneumonectomy at 15 sites throughout the UK. Planned sample size is 452 patients. Participants were randomised to either simvastatin 80 mg or placebo for 4 days preoperatively and up to 7 days postoperatively. MEASUREMENTS: The primary outcome measure was a composite endpoint of the incidence of acute respiratory distress syndrome, postoperative pulmonary complications, myocardial infarction and/or myocardial ischaemia during the first 7 days postoperatively or until hospital discharge. A modified intention-to-treat analysis excluded patients who did not receive the intervention preoperatively or proceed with the planned surgery. MAIN RESULTS: 251 patients were randomised, 126 assigned to simvastatin and 125 to placebo, with 208 included in the modified intention-to-treat population. The trial was stopped early because of futility following recommendations from the data monitoring and ethics committee. The primary outcome occurred in 45/106 patients (42.5%) in the simvastatin group and 39/102 patients (38.2%) in the placebo group (OR 1.19 (95% CI 0.68 to 2.08); p=0.54). Secondary and safety outcomes were similar between the groups. CONCLUSION: In patients undergoing one-lung ventilation, simvastatin did not reduce the incidence of postoperative cardiopulmonary complications. TRIAL REGISTRATION NUMBER: isrctn.org identifier, ISRCTN48095567.